Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? (2019)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1007/s12029-018-0166-4
- Subjects: ADENOCARCINOMA; NEOPLASIAS PANCREÁTICAS; NUCLEOSÍDEOS; QUIMIOTERÁPICOS; RESULTADO DE TRATAMENTO; QUIMIOTERAPIA ADJUVANTE
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of gastrointestinal cancer
- ISSN: 1941-6628
- Volume/Número/Paginação/Ano: v. 50, n. 4, p. 860-866, 2019
- Este artigo NÃO possui versão em acesso aberto
-
Status: Nenhuma versão em acesso aberto identificada -
ABNT
GIRARDI, Daniel M et al. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?. Journal of gastrointestinal cancer, v. 50, n. 4, p. 860-866, 2019Tradução . . Disponível em: https://doi.org/10.1007/s12029-018-0166-4. Acesso em: 13 mar. 2026. -
APA
Girardi, D. M., Faria, L. D. B. B., Teixeira, M. C., Costa, F. P., Hoff, P. M. G., & Fernandes, G. S. (2019). Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? Journal of gastrointestinal cancer, 50( 4), 860-866. doi:10.1007/s12029-018-0166-4 -
NLM
Girardi DM, Faria LDBB, Teixeira MC, Costa FP, Hoff PMG, Fernandes GS. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? [Internet]. Journal of gastrointestinal cancer. 2019 ; 50( 4): 860-866.[citado 2026 mar. 13 ] Available from: https://doi.org/10.1007/s12029-018-0166-4 -
Vancouver
Girardi DM, Faria LDBB, Teixeira MC, Costa FP, Hoff PMG, Fernandes GS. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? [Internet]. Journal of gastrointestinal cancer. 2019 ; 50( 4): 860-866.[citado 2026 mar. 13 ] Available from: https://doi.org/10.1007/s12029-018-0166-4 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
